Shionogi & Co. (TYO:4507) said it secured supplemental approval for the pediatric dosage and administration of its Xocova drug for the treatment of COVID-19 in Japan, according to a Friday release.
The Japan-based pharmaceutical company said that the approval expands the drug's usage among pediatric patients aged 6 to under 12 years who weigh at least 20 kilograms.
The approval also covers a new 25-milligram tablet and follows results from a Phase 3 clinical trial involving 117 children in Japan.